{
    "nct_id": "NCT01609348",
    "title": "Venlafaxine for Depression in Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2018-01-04",
    "description_brief": "This study will test the use of venlafaxine to treat the depression in Alzheimer's Disease. Venlafaxine works by increasing natural substances in the brain (serotonin and norepinephrine) that help maintain mental balance. Alzheimer's disease (AD) is the commonest neurodegenerative disease of aging and the cause of major financial and emotional burden to patients, families and caregivers, and society. Depression is a very common symptom of AD, affecting as many as 50% of patients over their illness. Depression in AD (Alzheimer's disease) contributes greatly to patient disability and caregiver distress. Neither psychosocial interventions nor psychotropic medications have proven effective to date for the treatment of depression in AD.Venlafaxine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depression but it is not known whether or not it can help depression in Alzheimer's Disease.",
    "description_detailed": "N/A",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Venlafaxine",
                    "description": "225 mg daily over 12 weeks\n\nVenlafaxine: 225 mg daily for 12 weeks"
                },
                {
                    "id": "FG001",
                    "title": "Sugar Pill",
                    "description": "Placebo: Capsule matching active drug to be taken once a day for 12 weeks"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Venlafaxine",
                    "description": "225 mg daily over 12 weeks\n\nVenlafaxine: 225 mg daily for 12 weeks"
                },
                {
                    "id": "BG001",
                    "title": "Sugar Pill",
                    "description": "Placebo: Capsule matching active drug to be taken once a day for 12 weeks"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "3"
                        },
                        {
                            "groupId": "BG001",
                            "value": "2"
                        },
                        {
                            "groupId": "BG002",
                            "value": "5"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "2"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "4"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change.",
                    "description": "Treatment will be considered efficacious if the proportion of worse categories (including 'minimal worsening', 'moderate worsening', or 'marked worsening') is lower under treatment than control on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change.\n\nClinical Global Impression of Change: This is a 7-item score ranging from \"markedly worse\" to \"markedly improved\". It is assessed by the study clinician who interviews both participant and informant and makes an informed judgment how to incorporate their input",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "12 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Venlafaxine",
                            "description": "225 mg daily over 12 weeks\n\nVenlafaxine: 225 mg daily for 12 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Sugar Pill",
                            "description": "Placebo: Capsule matching active drug to be taken once a day for 12 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "3"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "2"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Marked improvement according to CGI",
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Moderate improvement according to CGI",
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Venlafaxine",
                    "description": "225 mg daily over 12 weeks\n\nVenlafaxine: 225 mg daily for 12 weeks",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 3,
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 3,
                    "otherNumAffected": 1,
                    "otherNumAtRisk": 3
                },
                {
                    "id": "EG001",
                    "title": "Sugar Pill",
                    "description": "Placebo: Capsule matching active drug to be taken once a day for 12 weeks",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 2,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 2,
                    "otherNumAffected": 1,
                    "otherNumAtRisk": 2
                }
            ],
            "seriousEvents": [
                {
                    "term": "Hypokalemia",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 3
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 2
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 3
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 2
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 3
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 2
                        }
                    ]
                },
                {
                    "term": "Low potassium",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 3
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 2
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": true
            },
            "pointOfContact": {
                "title": "Paul Rosenberg, MD",
                "organization": "Johns Hopkins University",
                "email": "prosenb9@jhmi.edu",
                "phone": "410-550-9883"
            }
        }
    },
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "Venlafaxine (SNRI \u2014 serotonin and norepinephrine reuptake inhibitor)"
    ],
    "placebo": [
        "Placebo (sugar pill)"
    ],
    "explanation_target": [
        "Reason: The trial tests venlafaxine to treat depression in people with Alzheimer\u2019s disease \u2014 this is treating a neuropsychiatric symptom (depression) rather than targeting AD pathology such as amyloid or tau. \ue200cite\ue202turn0search9\ue202turn0search0\ue201",
        "Act (key details extracted): Intervention = venlafaxine (an SNRI that increases serotonin and norepinephrine levels); comparator = placebo (sugar pill). Venlafaxine is an FDA\u2011approved antidepressant (SNRI) with the described mechanism of inhibiting serotonin and norepinephrine reuptake. \ue200cite\ue202turn1search0\ue202turn1search3\ue202turn1search5\ue201",
        "Act (supporting literature / trial context): Prior randomized trials have examined venlafaxine for depression in dementia/older adults; the trial title given is \"Venlafaxine for Depression in Alzheimer's Disease.\" \ue200cite\ue202turn0search0\ue202turn0search9\ue201",
        "Reflect: Classification check \u2014 per the provided category definitions, venlafaxine is not a biologic nor a small molecule specifically targeting AD pathology, and its intended effect is to improve depression (a neuropsychiatric symptom). Therefore the correct category is 'neuropsychiatric symptom improvement'. \ue200cite\ue202turn1search1\ue201",
        "Web search results used: PubMed randomized trial of venlafaxine in dementia (venlafaxine vs placebo). \ue200cite\ue202turn0search0\ue201",
        "Web search results used: Trial listing (Venlafaxine for Depression in Alzheimer's Disease; MedPath / trial summary showing venlafaxine vs placebo). \ue200cite\ue202turn0search9\ue201",
        "Web search results used: FDA / prescribing information summary describing venlafaxine as an SNRI that increases serotonin and norepinephrine. \ue200cite\ue202turn1search0\ue202turn1search3\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests venlafaxine, an SNRI that increases synaptic serotonin and norepinephrine by inhibiting their reuptake. This is a symptomatic treatment acting on monoaminergic neurotransmitter systems rather than on core AD pathologies such as amyloid or tau. \ue200cite\ue202turn0search1\ue202turn0search8\ue201",
        "Act: Key details extracted from the description and literature \u2014 Intervention: venlafaxine (serotonin\u2011norepinephrine reuptake inhibitor); Indication in this trial: treat depression in people with Alzheimer\u2019s disease (neuropsychiatric symptom improvement); Comparator: placebo. A venlafaxine trial in AD (Venlafaxine for Depression in Alzheimer\u2019s Disease / DIADs\u20113) and prior randomized studies of venlafaxine in dementia/depression are documented. \ue200cite\ue202turn0search5\ue202turn0search6\ue202turn0search0\ue201",
        "Reflect: Classification check \u2014 CADRO category D (Neurotransmitter Receptors) best fits because the drug modulates monoaminergic neurotransmission (serotonin and norepinephrine) / their reuptake transporters, addressing neuropsychiatric symptoms via neurotransmitter system modulation rather than disease\u2011modifying targets (amyloid, tau, inflammation, etc.). The intervention is not multi\u2011target in the CADRO sense (it is a monoamine reuptake inhibitor) nor non\u2011therapeutic, so D is most specific. \ue200cite\ue202turn0search1\ue202turn0search8\ue201",
        "Web search results used (key sources):",
        "\u2022 FDA summary / prescribing context for venlafaxine (SNRI classification). \ue200cite\ue202turn0search1\ue201",
        "\u2022 Venlafaxine prescribing information / drug label summary (mechanism, dosing). \ue200cite\ue202turn0search8\ue201",
        "\u2022 Trial listing: Venlafaxine for Depression in Alzheimer\u2019s Disease (MedPath trial summary). \ue200cite\ue202turn0search5\ue201",
        "\u2022 Clinical trials registry listing for venlafaxine in depression & AD (study NCT/registry entry). \ue200cite\ue202turn0search6\ue201",
        "\u2022 Prior randomized placebo\u2011controlled trial of venlafaxine in depression with dementia. \ue200cite\ue202turn0search0\ue201"
    ]
}